This offering is relevant only to doctors. Please review session information and legal disclaimers before booking.

Under TGA laws, there are four approved pathways for doctors to access unapproved medical cannabis products, provided it is clinically suitable for their patients:

1. Authorised Prescriber - Established History of Use pathway
2. Authorised Prescriber - Standard pathway
3. SAS Category A notification pathway
4. SAS Category B application pathway

This session is tailored to assist doctors in navigating the Authorised Prescriber - Established History of Use pathway (1.).

Guided by our prescriber support specialist via an online video meeting, you’ll receive step-by-step assistance in applying for a minimum of four (4) Authorised Prescriber (AP) approvals, equipping you to prescribe medical cannabis to patients with qualifying needs.

In this 1-hour session, you will have the option to apply for AP approvals for specific, clinically-supported conditions, including:

• Refractory chronic pain in adult patients
• Refractory anxiety in adult patients
• Refractory sleep disorders in adult patients
• Refractory cancer pain in adult patients
• Refractory autism spectrum disorder in adult patients

Estimated Duration: 1 hour

Delivery Format: Online video meeting

Please consider the following prior to purchasing this session.

• SAGED online sessions do NOT offer medical prescribing advice to healthcare practitioners.
• SAGED will NOT complete applications on behalf of any healthcare practitioners.
• The Authorised Prescriber - Online Application Support session is designed to support practitioners throughout their TGA Authorised Prescriber application process. 
• SAGED does NOT take responsibility for the prescribing habits or practices of any healthcare practitioners.
• SAGED does NOT take responsibility for the outcome/decision of the TGA in certifying Authorised Prescribers.

Before applying to access an unapproved product, all prescribers should:

• consider approved products for your patient's medical condition
• consider risks of treatment
• obtain informed consent
• adhere to relevant standards of good medical practice
• check state and territory requirements
• check the product is available and affordable for the patient

SAGED asks all practitioners to read through following prior to attending their SAGED online session:

• TGA Medical Cannabis Hub
• TGA Authorised Prescribers
• TGA Applications and reporting
• TGA Special Access Scheme

For any questions, please contact hello@saged.com.au.

The Established History of Use pathway allows doctors to prescribe categories of medical cannabis products that contain lower proportions of THC, under controlled dosage forms and for adult patients with specific & tried medical conditions.

This pathway limits the prescription of medical cannabis to products within Categories 1, 2, & 3, which have been categorised based on the proportion of cannabidiol (CBD) relative to the total cannabinoid content.

Permitted categories under the Established History of Use pathway:

• Category 1: CBD medicinal cannabis product (CBD ≥ 98%)
• Category 2: CBD dominant medicinal cannabis product (CBD ≥ 60% and < 98%)
• Category 3: Balanced medicinal cannabis product (CBD <60% and ≥ 40%)

Note: Categories 4 and 5 (THC dominant products with THC 60-98% and THC >98%) are not available under this pathway.

Eligible conditions for prescription under this pathway include:

• Refractory chronic pain in adult patients
• Refractory anxiety in adult patients
• Refractory sleep disorders in adult patients
• Refractory cancer pain in adult patients
• Refractory autism spectrum disorder in adult patients

Permitted dosage forms:

• Oral liquids/oils
• Capsules

While SAGED charges a support fee for this online service, there are NO additional fees for submitting approval applications through the TGA's Established History of Use pathway. Doctors may apply for up to 18 approvals under this pathway at no additional cost.

However, for those seeking Authorised Prescriber approvals outside the Established History of Use pathway, additional fees and supporting documentation will be required.

Approvals under the Established History of Use scheme are limited to the following five conditions for adult patients:

• Refractory chronic pain
• Refractory anxiety
• Refractory sleep disorders
• Refractory cancer pain
• Autism spectrum disorder

The Established History of Use scheme limits Authorised Prescriber approvals to two dosage forms:

• Oral liquid/oil
• Capsules

Approvals under the Established History of Use scheme are limited to the following three product categories:

• Category 1: CBD medicinal cannabis product (CBD ≥ 98%)
• Category 2: CBD-dominant medicinal cannabis product (CBD ≥ 60% and < 98%)
• Category 3: Balanced medicinal cannabis product (CBD < 60% and ≥ 40%)

The following product categories are NOT included:

• Category 4: THC dominant medicinal cannabis product (THC 60-98%)
• Category 5: THC medicinal cannabis product (THC >98%)

No, this session is focussed solely on supporting prescribers through the application pathway and will not provide product recommendations or educational guidance on specific medical cannabis products.